Verified Nov 2026
Other
·

·
Since 2000
Tris Pharma is a privately held biopharmaceutical manufacturer headquartered in Monmouth Junction, New Jersey, founded in 2000. With 500–1,000 employees and estimated revenue of $50–100 million, the company develops and commercializes medicines for central nervous system disorders including ADHD, pain, and addiction. It employs proprietary sustained-release technology called LiquiXR to create prescription and over-the-counter formulations, and recently expanded into digital health diagnostics for neurological conditions.
Tris Pharma at a glance
Revenue
$50-100M
Est. band
Employees
500-1,000
Founded
2000
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Overview
Tris Pharma is a privately held biopharmaceutical manufacturer headquartered in Monmouth Junction, New Jersey, founded in 2000. With 500–1,000 employees and estimated revenue of $50–100 million, the company develops and commercializes medicines for central nervous system disorders including ADHD, pain, and addiction. It employs proprietary sustained-release technology called LiquiXR to create prescription and over-the-counter formulations, and recently expanded into digital health diagnostics for neurological conditions.
At a glance
Attribute | Detail |
|---|---|
Founded | 2000 |
Employees | 500-1,000 |
Revenue | $50-100M (estimated) |
What Tris Pharma makes
The company holds over 150 patents and uses its proprietary LiquiXR sustained-release technology platform to develop diverse dosage forms for extended-period medication delivery.
Latest developments
2026-08-12 — Tris Pharma Expands Support for People Living with ADHD Through New Partnerships with Calm Health and ADHD Central - BioSpace (biospace.com)
2026-06-10 — Tris Pharma Announces FDA Grant of Orphan Drug Designation (globenewswire.com)
2026-06-08 — We’re pleased to see our partner Kye Pharmaceuticals expanding access to care for individuals living with ADHD across Canada. (linkedin.com)
2025-12-09 — Tris Pharma Announces FDA Acceptance of NDA for Once-Nightly, Low-Sodium Oxybate Product for Narcolepsy and Idiopathic Hypersomnia (businesswire.com)
2025-08-06 — Pulse Health partners with Tris Pharma to Power Omnichannel HCP Engagement for ADHD Products (prnewswire.com)
Company details
Tris Pharma serves patients, healthcare providers, and pharmacies as a specialty pharmaceutical player with a pipeline of candidates and received FDA orphan drug designation in June 2026. Tris Pharma was founded in 2000, and has an estimated 500-1,000 employees.
Frequently asked questions
What does Tris Pharma do?
Tris Pharma is a privately held biopharmaceutical manufacturer headquartered in Monmouth Junction, New Jersey, founded in 2000. With 500–1,000 employees and estimated revenue of $50–100 million, the company develops and commercializes medicines for central nervous system disorders including ADHD, pain, and addiction. It employs proprietary sustained-release technology called LiquiXR to create prescription and over-the-counter formulations, and recently expanded into digital health diagnostics for neurological conditions.
When was Tris Pharma founded?
Tris Pharma was founded in 2000.
How big is Tris Pharma?
Tris Pharma has an estimated 500-1,000 employees, with revenue in the $50-100M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
